Table 3 Changes in eGFR value according to renal function decrease
From: Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients
Observation period, months | Group D | Group ND | ||||||
|---|---|---|---|---|---|---|---|---|
Number of patients | Absolute value, (mL/min/1.73 m2) | Changed value, (mL/min/1.73 m2) | p-value | Number of patients | Absolute value, (mL/min/1.73 m2) | Changed value, (mL/min/1.73 m2) | p-value | |
0 | 13 | 83.9 ± 16.2 | – | – | 27 | 69.6 ± 17.0 | – | – |
1 | 13 | 71.9 ± 20.9 | −12.0 ± 11.4 | 0.0033 | 27 | 63.5 ± 2.9 | −5.3 ± 12.6 | 0.0403 |
3 | 13 | 74.2 ± 19.9 | −9.6 ± 9.9 | 0.0057 | 27 | 67.1 ± 16.1 | −2.8 ± 10.6 | 0.1874 |
6 | 13 | 71.0 ± 22.3 | −12.9 ± 8.9 | 0.0003 | 27 | 67.9 ± 17.2 | −2.1 ± 11.7 | 0.3697 |
12 | 13 | 70.3 ± 18.7 | −13.5 ± 7.1 | < 0.0001 | 25 | 71.2 ± 21.9 | 0.1 ± 11.4 | 0.9605 |
18 | 13 | 72.5 ± 25.4 | −11.4 ± 15.9 | 0.0295 | 19 | 68.8 ± 19.1 | −0.47 ± 10.6 | 0.8533 |
24 | 12 | 66.6 ± 25.5 | −18.3 ± 17.6 | 0.0009 | 15 | 66.6 ± 15.3 | −5.93 ± 10.7 | 0.0571 |
30 | 11 | 59.8 ± 22.0 | −25.6 ± 11.0 | < 0.0001 | 10 | 65.8 ± 18.1 | −8.5 ± 12.9 | 0.0791 |
36 | 7 | 54.9 ± 16.6 | −28.5 ± 9.4 | 0.0003 | 8 | 67.1 ± 19.6 | −9.4 ± 9.5 | 0.0346 |
42 | 7 | 52.3 ± 13.5 | −31.1 ± 10.9 | 0.0004 | 8 | 68.4 ± 17.3 | −8.1 ± 7.6 | 0.0252 |
48 | 6 | 52.3 ± 15.3 | −29.0 ± 11.0 | 0.0020 | 6 | 66.7 ± 12.6 | −11.5 ± 5.4 | 0.0136 |
54 | 3 | 46.3 ± 6.4 | −25.0 ± 1.7 | 0.0022 | 3 | 88.4 ± 34.6 | 0.9 ± 11.9 | 0.9276 |
60 | 1 | 48.6 | −23.4 | n.c. | 2 | 97.6 ± 20.4 | −6.3 ± 5.2 | 0.4393 |